Mohammad Mahboob Alam

The ligand 3-(-(2-hydroxyphenylimino) methyl)-4H-chromen-4-one (SL) has been synthesized and examined as a chemosensor for some metal ions in aqueous solutions based on colorimetric analysis. Color changes were monitored using UV–visible spectroscopy. Binding stoichiometry and limit of detection (LOD) were estimated using titration experimentation based on UV–visible absorbance and Job’s plot. The synthesized ligand was tested for selectivity in the presence of several cations and was examined for possible utility as a chemosensor in real water samples. The results indicated sensing ability and selectivity for Cu2+, Fe3+, and V5+. Stable complexes were formed between SL and Cu2+, Fe3+, and V5+, and the ligand-to-metal binding stoichiometry was found 2 : 1 in the SL-Cu2+ and SL-Fe3+ complexes, and 1 : 1 in the SL-V5+ complex. The results of LOD and bending constant were (7.03 μM, 1.37 × 104 M−1), (5.16 μM, 2.01 × 104 M−1), and (5.94 μM, 1.82 × 104 M−1) for Cu2+, Fe3+, and V5+, respectively.

In the present work, new benzimidazole based 1,3,4‐oxadiazole linked thioacetamide conjugates have been synthesized and evaluated for antiproliferative activity. Formation of all the target molecules were elucidated by NMR ( 1 H & 13 C), FTIR, mass spectrometry and other techniques. The compounds displayed significant to moderate cytotoxicity towards MCF‐7, HepG2 and HCT‐116 cancerous cell lines. Among all the compounds, compound 11 , 12 and 13 showed promising cytotoxicity with IC 50 2.39–10.98 μM, 4.57–16.35 μM and 3.10‐15.58 μM towards MCF‐7, HepG2 and HCT‐116, respectively. Also, compound 11 , 12 and 13 inhibited EGFR with IC 50 0.91–2.1 μM and exhibited high binding energy of −8.34, −8.06 & −8.08 Kcal/mol, respectively against EGFR protein in docking study. The DFT study was also found to be consistent with the anticancer results of these newly synthesized compounds. It can be concluded that these 1,3,4‐oxadiazole based benzimidazole derivatives possess promising anticancer properties and could be used as anticancer leads.